Presentation at mHealth Israel Investors Summit by Tom Sudow, Head of Business Development: "Successful Commercialization – The Cleveland Clinic Story". The mission is to promote Innovation via Commercialization by bringing new innovations into widespread clinical practice, protecting the intellectual property underlying the innovations, optimizing the value returned for those innovations, and growing the regional economy.
Building A Global Brand Through Content MarketingLiveWorld
This presentation will discuss how the Cleveland Clinic has established itself as one of the premier healthcare brands in the world through innovative and creative content marketing. Paul Matsen will describe how Cleveland Clinic creates distinctive and trusted content to build awareness, reputation and to generate volume. The Cleveland Clinic has been a leader in digital, social and mobile healthcare marketing and employees a unique mix of paid, earned and owned media to build its brand.
Building A Global Brand Through Content MarketingLiveWorld
This presentation will discuss how the Cleveland Clinic has established itself as one of the premier healthcare brands in the world through innovative and creative content marketing. Paul Matsen will describe how Cleveland Clinic creates distinctive and trusted content to build awareness, reputation and to generate volume. The Cleveland Clinic has been a leader in digital, social and mobile healthcare marketing and employees a unique mix of paid, earned and owned media to build its brand.
Arvind eye care hospital by vikrant methavikrantm007
This PPT helps to understand the management of Arvind care hospital and also explain business model, PESTAL analysis, SWOT analysis, STP process and 4P,s of marketing about arvind eye care hospital.
Most reliable diagnostic and pathology center to watch..Merry D'souza
This edition of Most Reliable Diagnostic and Pathology Centres to Watch places the spotlight on healthcare service providers that are leveraging such revolutionary technologies to deliver the best to those seeking their services.
At Marketing Vision Consulting pride ourselves on realizing with keen insight the complexity and intricacies of the development and commercialization of new products and offerings. We bring expertise in the areas of biotechnology, pharmaceuticals, diagnostics, medical device, and healthcare services.
Arvind eye care hospital by vikrant methavikrantm007
This PPT helps to understand the management of Arvind care hospital and also explain business model, PESTAL analysis, SWOT analysis, STP process and 4P,s of marketing about arvind eye care hospital.
Most reliable diagnostic and pathology center to watch..Merry D'souza
This edition of Most Reliable Diagnostic and Pathology Centres to Watch places the spotlight on healthcare service providers that are leveraging such revolutionary technologies to deliver the best to those seeking their services.
At Marketing Vision Consulting pride ourselves on realizing with keen insight the complexity and intricacies of the development and commercialization of new products and offerings. We bring expertise in the areas of biotechnology, pharmaceuticals, diagnostics, medical device, and healthcare services.
This is a 20-minute lecture covering points to consider when building value proposition unique to medical technology. It begins with a brief review of issues related to market adoption for medical technology and the hurdles that a medical technology innovator may encounter when taking a product to market. You will learn about the 7 key factors that would boost market fit.
http://semoegy.com
Innovation & Technology Commercialization for NursesWhitney Power
This presentation was designed to inspire nurses to invent solutions to problems in the health care industry. It is presented by the Technology Commercialization Manager to nurses - and adapted for other audiences as needed. It was designed by Whitney Power to align with other department promotion/informational materials.
Marketing Strategy for a medical device companysaurabhmalani
This is a marketing strategy for a leading medical device company for a new product launch. This presentation won the Babson Marketing Case Competition - 2012 with prize money of $5000. 16 schools across the globe were competing in this competition.
Putting innovation into practice (NHS vs Widnes Vikings)Richard Harding
Where is the Front Door to the NHS?
How do we procure innovation and innovate procurement in Health?
What does health want?
How does an SME leverage Local Infrastructure
Baptist Health- Engineering the Future of HealthcareLevi Shapiro
Presentation by Mark Coticchia, Chief Innovation Officer, Baptist Health, for mHealth Israel community, September, 2023. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences.
A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies.Innovation is paramount to health system’s performance and reputation.
Becker’s 2019 Advisory Board survey revealed innovation and technology ranked as the top priority among healthcare finance professionals - up from eighth in 2018. 90% healthcare/life science leaders agree that the pandemic will fundamentally change the way they do business, requiring new products, services, processes, and business models (McKinsey: Innovation Through Crisis Survey). Innovation has been proven to help health systems in many ways. A capability and culture of innovation accomplish numerous goals:
Innovation capability and culture improve the care and work environment. They enhance the reputation through recognition for discoveries made at and through Baptist Health. They aid in the recruitment and retention of top talent. And they help systems harness money that otherwise would be leaving the system – licensing revenues and investment returns and corporate research support and donor revenues. Successful Programs - Common Underpinnings. Innovation as a strategic, institutional priority
Program built on institutional assets and centers of excellence
Experienced, professional team
Technology development and sourcing, Dedicated, long term support. Doing healthcare innovation well at a large enterprise takes a highly specialized team and skill set. Collectively, they need to have deep knowledge of healthcare regulation, medical procedures, patient safety, business development, transactions, business law, innovation markets, entrepreneurship, venture capital, commercialization, tech transfer, organizational change management, and much more. Programs- services, technology management, corporate co-creation, global medical service lines and facilities; Focus on market opportunity vs. technology; Select & concentrate on winners; Operate as a business; Proactive in new company formation; Progress, milestones, preliminary results; Building New Innovation Pathways; Improving Treatment for Cancer Patients; Predicting & Preventing Heart Attacks; Improving Outcomes in Cardiac Care; Enhancing a Culture of Innovation at Baptist Health & South Florida; Cleerly, TriVentures, COTA; Innovation is paramount to health system’s performance and reputation.
Baptist Health has established an innovation function predicated on best practices and tailored to its assets and the opportunities extending from Miami’s economic growth
Tate Campbell, Change Healthcare - Extracting Knowledge from Healthcare Data ...Sri Ambati
This session was recorded in San Francisco on February 5th, 2019 and can be viewed here: https://youtu.be/Bd7Y2tGKgys
Tate Campbell is a Data Scientist at Change Healthcare specializing in Big Data and Cloud Technologies. Tate has experience as a practicing Data Scientist in the healthcare, legal, and marketing industries. Tate studied biochemistry and mathematics at California State University, Chico and holds a Master’s degree in Analytics from the University of San Francisco.
Take your Idea. Develop your Product. Test it, Sell it, and Exit. Innovative clinical minds face difficulties actualizing great product ideas because of the complexities associated with healthcare product development. A successful healthcare innovation development process involves integrating many complex disciplines at the highest level of quality in order to provide patients with the safest and most effective treatment options. As a result, many innovators never begin to develop their ideas because of intimidation or lack of resources. Some innovators go through the stressful and costly undertaking of an improvised development process that ultimately leads to a less than optimum product and poor financial returns. In order to solve this problem, we created a comprehensive platform to efficiently translate ideas into effective and successful healthcare products.
Chris Cleary, Vice President of Corporate Development, Medtronic presented at MEDTECH 2014 on Fulfilling the Mission: Medtronic Embraces Change to Respond to an Evolving Healthcare Landscape.
Increasing the success rate of developing startup-corporate partnerships by a structured program to build and validate a joint value story
by Kors van Wyngaarden, Medical Officer @Philips HealthWorks
Based on extensive experience in engaging with startups in 12 weeks programs Philips HealthWorks is continuously tweaking their approach to increase the value of sustainable partnerships between Philips and Healthcare startups. Kors will share how HealthWorks uses a structured approach, stakeholder and ecosystem engagements to help startups increase their own value and, in parallel, to build and validate the partnership value story.
Karen Livingstone - ECO 17: Transforming care through digital healthInnovation Agency
Presentation by Karen Livingstone, Director of Innovation Exchange and SBRI Healthcare, NHS England: Transforming Health and Social Care Services - The Innovation Exchange and SBRI Healthcare at ECO 17: Transforming care through digital health on Tuesday 4 December at Lancaster University, Lancaster
The external healthcare environment is changing rapidly and providers are under increasing pressure to innovate with increasing speed and efficiency.
Be it experimenting with new care delivery models to improve care coordination, redesigning workflows to enhance efficiency, or developing new products that improve clinical outcomes, hospitals and their service lines are looking for effective ways to harness the creative power of physicians and employees to solve problems that matter. However, few organizations innovate in an orderly, reliable way.
Great ideas remain captive in the heads of physicians and employees and one-off attempts to spur innovation through “hack-a-thons” and “pitch days” prove disappointing. As an academic medical center and a world leader in orthopedics, Hospital for Special Surgery has a long history of results-oriented innovation.
In this webinar, we will share:
– HSS’ systematic approach for driving innovation
– strategies for generating new insights and developing novel solutions
– processes for piloting and testing new ideas
– guiding principles for creating a culture of innovation
– advice on how to build your very own innovation infrastructure
About the Speaker:
Mark Angelo is Vice President, Innovation & Business Development for Hospital for Special Surgery. Mark joined HSS in 2009 and has held various senior management positions at the Hospital across operations, strategy and business development. As Vice President, Innovation & Business Development, Mark is responsible for advancing hospital strategic priorities related to quality and efficiency, innovation, growth and diversification. One of his key responsibilities includes leading the Operational Excellence program, a hospital-wide initiative that leverages industrial engineering principles to maximize quality and efficiency. Mark also leads the HSS Innovation Center whose mission is to support the development and commercialization of early-stage technologies and solutions.
Prior to joining HSS, Mark worked as a management consultant for Monitor Group where he specialized in operations strategy and organizational design. Mark holds a Bachelor of Applied Science in Biomedical Engineering from the University of Toronto and a Master of Business Administration from Harvard Business School.
The Role of Health Research Wales in supporting Industry Research in Betsi Cadwaladr University Health Board (BCUHB)
International Clinical Trials Day 20th May 2014
Presented by Rebecca Burns, Health Research Wales, Industry Manager
Overview of Lodestone Logic services including business intelligence, strategic planning, and project execution. This presentation also includes a summary of Lodestone Logic's media channels and web presence.
Similar to mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015 (20)
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
mHealth Israel_Healthcare Finance and M&A- What Comes NextLevi Shapiro
Healthcare Finance and M&A, What Comes Next? Presentation by Matthew R. Kittay, National Co-Chair, M&A Practice Group, Fox Rothschild LLP. Includes fundraising and investments. Breakouts by subsector- Healthcare (overall), Healthcare services, Digital health, Biopharma, Pharmatech, Medtech, Healthcare IT. Healthcare transaction distribution breakouts. Exits remain flat. Avoiding common legal pitfalls like IP, compliance, governance structure. Current legislation in health law. IP strategy for healthtech.
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Levi Shapiro
Oppenheimer & Co. Inc, co-Head of Healthcare Investment Banking, Michael Margolis, provides H1 Healthcare Financing, Funding and M&A Overview. Table of Contents
1. Broader Market Overview
2. Biotech M&A Market Overview
3. Private Biotech Financing Market Update
4. Key Advice For Healthcare Companies
Current State of Play; Healthcare has Underperformed the Broader Market Over the Last Twelve Months; Signal-to-Noise is Getting Worse; Healthcare IPO Activity has Decreased Significantly Since 20–21 Pandemic Levels; Biotech Financing Activity Has Remained Robust in 2024; Biotech M&A Market Remains Incredibly Active; Biotech M&A Market Remains Incredibly Active; Big Pharma Upcoming Patent Expirations; Since November 2023 Oncology has accounted for over half of all M&A; Oncology, Autoimmune / I&I, and CV & Metabolic Remain the Top Areas in M&A; Small Molecule Beats Out All Other Modalities in M&A Despite IRA Concerns; Value of Big Pharma Acquisitions by Therapeutic Area in Q1 2024; Private Financing Market Update; 2024 Private Placement Activity On Track to Approach, If Not Exceed, 2020 Levels; Oncology, Particularly Solid Tumor, Continues to Attract VC Investors; Despite the IRA, Small Molecules Continue to Attract VC Dollars; Preclinical-Stage Companies Make Up Almost Half of Private Placements in 2023; Valuations by Development Stage – 2023; Typical Biotech Investors Remained Active in Q1 2024; 23 $100M+ Deals were Raised in Q1 2024; Biotech Fundraising Momentum Continued into 2024; Key Advice For Israeli Healthcare Companies; Although Israel has Strong Presence on US Public Markets, There is Room to Grow; Telling Your Story Effectively; Interacting with Investors to Build Long-term Credibility; Seven Simple Rules for Pitch Decks;
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003Levi Shapiro
Description of the Version Bravo intensive entrepreneurial launch program for 7 Israeli and 7 US former Navy SEALs. Details about each startup concept, the CEOs, the sector, etc.
Radical Life Extension_Dr. Leon Peshkin_Dec 2023Levi Shapiro
Presentation for mHealth Israel by Dr. Leon Peshkin, Harvard Medical School, exploring research into Embryology and Longevity, emphasizing Germline and protein aggregates. Includes current overview, anti aging through history, Lifespan Expansion, ALEC: Animal Life Expectancy in Controls, Scalable Platform in Pharmacobiology, Embryos Cleanse Protein Aggregates, Lysosomal switch triggers proteostasis renewal, Xenopus, Rejuvenation Roadmap, Citizen Science Approach to Aging, Xenopus: Maternal Dowry Molecules, Human Disease Modeling
Israel’s Life Science Hub 2023 English Abstract.pdfLevi Shapiro
The war between Israel and Hamas brings its own set of business
challenges. Challenges that may impact how we communicate with
partners and investors abroad. We should portray the life science sector as resilient and adaptable, even in times of crisis. This document is a a messaging outline for Israel's Life Science Hub despite the war with Hamas. Four key points to emphasize:
1) Global activity (resilience and agility)
2) Continuity of care and preventive medicine
3) World leading clinical trials industry
4) Dynamic scientific, research and entrepreneurial ecosystems
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...Levi Shapiro
The Future of Digital Health – Nose Dive or Transformation, by Gil Bashe, Dec 4th, 2023 at the mHealth Israel conference. Digital Health Innovation Ecosystem Investment Trends. Data & Methodology. Digital Health Taxonomy. Key Insights for Digital Health Innovation in H1 2023. Global Digital Health Funding Across Regions. Funding in North America. Shifting Focus in North America Digital Health Funding. Investment Focus for Digital Health Venture Funding. Ventures are turning to partnerships for proof points, scale and funding. 2022 new partnerships. North America digital health investor participation. Most active partners in North America. North America Ecosystem Development. Venture distribution by stage. Funding distribution. Comparison to 2022 Funding. Noteworthy deals, noteworthy exits.
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MITLevi Shapiro
We, 465 MIT Alumni, Staff, and Students, are writing to express our deep concern, fear, and disappointment regarding the recent protest that took place Thursday afternoon, in front of the MIT Stratton Student Center. While we fully support the principles of free
speech and the right to peaceful assembly, it is essential that we also prioritize the safety and well-being of all members of the MIT
community.
During the protest, a particular slogan was prominently displayed and chanted, which has raised significant concerns. The slogan
"From the [Jordan] river to the [Mediterranean] sea, Palestine will be free!" has been a source of contention due to its potential
implications and the real safety risks it poses to Jewish and Israeli students on campus [See video footage attached]. This slogan
has been time and again associated with calls for the destruction of the State of Israel and has been used in contexts that
promote violence, which raises legitimate concerns about the safety and security of our Jewish and Israeli students and staff.
Furthermore, we would like to draw your attention to recent events that demonstrate the potential dangers associated with this
slogan. During the 2023 Israel-Hamas war, British Home Secretary Suella Braverman proposed criminalizing the use of the slogan
in certain contexts, recognizing the potential harm it can cause. Additionally, on October 11, ‘23, Vienna police banned a
demonstration, citing the inclusion of the phrase "from the river to the sea" in invitations, as it was seen as a portrayal of a violation
of Article 2 of the European Convention on Human Rights.
In addition to the use of these derogatory messages, several attendees of the event used hateful wordings and messages towards
Jewish and Israeli bystanders. In one case, a perpetrator aggressively held their bicycles as intended to harm a Jewish MIT student,
stating that “[your] ancestors did not die in the Holocaust so they could kill Palestinians” [See video footage attached]. In another
incident, protesters chanted “one solution, intifada revolution”. In the context of the on-going Israeli-Palestinian conflict, the word
"Intifada" means the armed and violent Palestinian insurrection targeting Israelis, including civilians, which resulted in the killing of
thousands of Israelis in the last few decades.
On Oct. 22nd, a statement by MIT CAA (Coalition Against Apartheid) came to our attention. In this document, MIT CCA states that
they "hold the Israeli regime responsible for all unfolding violence". They later call the October 7th terror attack a "response to
the settler colonial regime", and continue justifying it throughout the document.
In this matter, MIT CAA is justifying the heinous and barbaric crimes committed on Oct 7th. Furthermore, these statements have the
potential to fuel acts of aggression
Overview of the Israeli exhibitors at the 2023 HLTH conference in Las Vegas. Exhibitors included 6Degrees, AppScent, Belong.Life, Datos, Expecting, IntraPosition, Kahun Medical, Kemtai, Maverick, Neteera, QuantaIX, Respiration Scan, Nerivio, Xoltar.
40% of Israeli technology investment is devoted to Life Science. Within that domain, the largest sector is Medical Devices and Digital Health (over 65 percent of companies). In the medical device arena, Israeli scientists and engineers have integrated advanced technologies in electronics, communications and electro-optics to develop world-class innovations in Digital Imaging, Medical Lasers, Telemedicine, Early Diagnostics,
Smart Surgical Equipment and more. Over 600 medical device exporters engaged in a variety of medical application
such as Cardiovascular and Peripheral Vascular, Neurology and Degenerative Diseases, Preparedness and Emergency
Medicine, Intensive Care, Women Health, Orthopedics and Sport Medicine, Gastrointestinal, Infection Control, Ophthalmology, Pain and Wound Management, Oral and Dental Care, Dermatology and Aesthetics
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...Levi Shapiro
Presentation by Yael Klionsky, YEDA, for the mHealth Israel community in September, 2023. Title: Challenges in Academic Technology Transfer. Examples-
Transplantation Immunology and Immunometabolism. Efranat Pharma was developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. From target discovery to clinical validation. Clinical-stage drug discovery and development company utilizing a broadly applicable, predictive
computational discovery platforms to identify novel drug targets and new biological pathways and develop
therapeutics in the field of cancer immunotherapy. To allow SOCIETY to benefit from discoveries made at the academic institution. To enable SCIENTISTS to transfer their new technologies to the market. To create an additional source of INCOME for the INSTITUTE so that more independent research can be conducted. Three important elements that make an idea patentable:
1) The invention must be new: the same idea can’t have been
published before in any form; 2) There must be some inventive step of ‘non-obviousness’.
This can be hard to define and depends on the context; 3) The disclosure in a patent must be sufficient for a skilled
person to reproduce the invention with only routine effort; Technology Transfer Company - modus operandi; OUR PURPOSE- To provoke transformative scientific breakthroughs that will shape the future of humanity; SCIENTIFIC STAFF- 300 Principal investigators, >2,000 Research students and PhDs; 5 FACULTIES – BASIC SCIENCE, Biology, Physics, Biochemistry, Math/CS
Chemistry; Generated IP- 57% in Life Science & Biotech; Among the Highest
Income per Researcher
Worldwide; 1959 (First TTO outside the US); Today- More applications per PI than in most Ivy league universities; Copaxone- >$30B
ANNUAL SALES BASED ON Weizmann IP; 20 new licenses per year and 10 new companies per annum; www.yedarnd.com
HADASIT: Tech Transfer and More in Life ScienceLevi Shapiro
Overview of activities in Life Science of Hadasit, the technology transfer arm of Hadassah Hospital in Jerusalem. Includes details about Jerusalem Biodesign program; spinouts like Brainwatch; details about tech transfer (the Secret Engine Behind Israel’s Success); relationship and examples of TTOs enabling Israel's greatest success stories; contrasting of Adademia (Scientific driven research, Creation of new knowledge, Publication, Sharing of Material, Social responsibilities) and Industry (Applied research & specific objectives, Develop new products, Product development, Secrecy and patent protection, Organization responsibilities); Development gap between initial inventions and product development; the Art of translation (from academic research to medical companies); Tech transfer transforms cutting-edge research into marketable healthcare technologies; LICENSING TO EXISTING COMPANIES; SPINNING OFF STARTUPS; CO-DEVELOPMENT OF JOINT IP; Technology Transfer Offices from Academia/Research Hospitals – to Industry; Overview of Hadassah and Hadasit (TECHNOLOGY TRANSFER COMPANY AND INNOVATION ENGINE OF HADASSAH UNIVERSITY HOSPITALS); Examples of “HADASSAH MADE” PRODUCTS IN THE GLOBAL MARKET; RECENT TECH TRANSFER SUCCESS; Example- Lineage Exclusive Worldwide Collaboration with Genentech Opregen® RPE Cell Therapy for the Treatment of Ocular Disorders; HADASIT PILLARS-
NURTURING INTERNAL INNOVATION, Tech Transfer, EXTERNAL INNOVATION. External- SERVICES & COLLABORATIONS WITH COMPANIES, BIOHOUSE FOR STARTUPS, DIGITAL HEALTH ACCELERATOR); Internal Innovation- NURTURING INTERNAL INNOVATION, HADASSAH SEED FUND, JERUSALEM BIODESIGN PROGRAM; TYPES OF RELATIONS WITH EXTERNAL COMPANIES- CONSULTING, SAB, CLINICAL TRIALS, R&D SERVICES, DATA LICENCE, ALPHA/BETA SITE, PILOTS, DESIGN PARTNERSHIPS.
Presenting to Investors & the Media.pdfLevi Shapiro
Presenting to Investors and the Media, lecture by Drew Levinson, LifeSci Communications to mHealth Israel. Three sections: Making a good presentation, Handling
interviews with reporters and Answers that resonate. PRESENTING TO INVESTORS AND THE MEDIA- Compelling delivery, Commanding a room, • Lasting Impact. A good presentation includes Information, Motivation and Excitement. Never put them to sleep. Audience impact includes content, credibility and delivery. Decisions are made leading to potential partnerships, winning business, so much more than a deck, your business, your brand, you. How to captivate begins with storytelling and conversation. More than features- benefits, humanize, positive impact. Don't complicate your message with jargon. Feel the passion- contagious, vision, determination. Know your audience- who are they, what do they know about you, how much do they know, interests, concerns. Articulate your vision- see it, feel it, believe in it. Take them on your journey- compelling narrative, make it personal, why are you doing this, inspiration. Your team- experienced, knowledgeable, aligned, execute. Risks and challenges- recognize, address, plan to mitigate. Test drive your room. What does it look like? Where is the podium? Where will I be standing? Where will you be sitting? Feel comfortable. Three parts to attention. The beginning- attention, interest, what's in it for them, entusiasm, preview. The middle- core, insights, challenges, solutions, relatable. The ending- summary, reinforce, messages, benefits, call to action, keep the momentum going. How to answer questions. The Four R's: repeat, reinforce, refer, remember. Talking to reporters- necessity; Good interview can enhance reputation; Bad interview can tarnish reputation; Preparation is vital. Shapes public opinion: Elevates your brand; Establishes authority; Showcases your business; A bridge; Reputation; Trust; Visibility. Know the reporter. Audience; What have they written; Previous stories; Questions asked. Concise- clear, succinct, engaging. Make it relatable: Stories; Anecdotes; Experiences; Examples; Metaphors; Connect. Honesty and transparency. It is okay not to know every answer. You don’t have to answer every question. Control the narrative. What not to do when talking to reporters. Come up with another way to say no comment. What to wear- solid colors, blues and grays, nothing distracting. Expertise, passion, vision, lasting impression, connections. High stakes, high rewards. Preparation; Know your audience; Deliver with confidence; Enthusiasm; Authenticity. Begin the journey. Engage in dialogue; Build relationships; Inspire trust and confidence; Valued; Enlightened; Motivated and excited.
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...Levi Shapiro
Presentation by Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgical Navigation Company and What's Next for XR. Covers the company founding across multiple milestones and key success factors.
Beyeonics CEO, Ron Schneider, Advances in Medical XRLevi Shapiro
Overview by Beyeonics CEO, Ron Schneider, about the company. Beyeonics One is the first ophthalmic exoscope with an augmented reality surgical headset. It is a high-definition, fully digital imaging platform enabling surgeons to see a magnified, three-dimensional (3D) image of the surgical field. The small footprint, the fast setup, automation, and zero turnover time between procedures all contribute to the efficiency operating rooms strive for. Over 3000 cases to date. Unconstrained Movement. Unconstrained workflow. Data connectivity. Designed for continuous innovation.
XRHealth is revolutionizing healthcare, bringing patient care into the Metaverse. Includes a description of the TeleHealth Platform. Lessons Learned – Building the clinical Metaverse. Last mile delivery
Building a product in the Metaverse is easy – getting people to use it is hard. Virtual Care can’t be based only on XR. HMDs bring friction – Charging, Guardian, Safety, Passwords etc. Expanding virtually in a brick & mortar payer environment. Once you cross the chasm – adherence/ satisfaction/retention goes ballistic. Patient Outcomes-
Patients report significant improvement in symptoms following treatment. Adherence - patients follow Home Exercise Plans as prescribed. 92.2% with XRHealth vs 50% with regular treatment. Patient satisfaction - 85 NPS vs 38 NPS in healthcare
93.3% patient retention -complete treatment cycle as prescribed. XRHealth Luna AI Reduces Hot Flashes and Improves Psychological Well-Being in Women with Breast and Ovarian Cancer: A Pilot Study. Virtual reality immersion compared to monitored anesthesia care for hand surgery: A randomized controlled trial. Lessons Learned – Autism Spectrum Disorder. The future of the Mediverse.
Digital Health in US Health Systems.pptxLevi Shapiro
April, 2023 presentation by Gil Bashe, Global Chair, Health Practice, FINN Partners. Insights and analytics, in collaboration with Galen Growth, tracking Digital Health collaboration, adoption, integration, and best practices across the leading US Health Systems. There is a section about focus areas for digital health in health systems and hospitals. The most active health systems are partnering more in diagnosis and have a higher share of digital tools for research. Comprehensive breakout of digital health activities at the Top 10 players: Mayo, Mount Sinai, Cleveland Clinic, Sloan Kettering, Massachusetts General, Northwell, Cedars Sinai, Brigham & Women's, InterMountain. Global breakout of health systems with digital health partnerships at scale. Geographical breakout of digital health partner headquarters (by region). Strong preference for B2B business model. 1/3 of digital health partnerships with Early Stage venture companies. Emphasis is on strong clinical evidence. Portfolio size allows greater diversity. Cluster distribution depends on therapeutic area. Digital health analytics breakout including alpha score, venture similarity score, venture valuation, team signal, partnership signal, evidence signal.
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...Levi Shapiro
Syllabus for the Future of Digital Medicine course, 2023- Biology, Genetics, Technology and BioInformatics. Includes lectures from Noam Shomron, Michal Rosen-Zvi, Eyal Zimlichman, Gila Tolub, Dana Bar-On, Yesha Sivan, Vladi Dvoryis, Varda Shalev, Avi Schroeder, Christian Tidano, Eyal Toledano.
Alagene BioFoundry: Releasing the Genie Out of the Bottle Levi Shapiro
Overview of Israel's leading BioFoundry, Alagene by Roni Cohen, CEO. Overview of Synthetic Biology- Taking biology into engineering mode. Using synthetic genes, to program cells to become factories to make devices, sensors, pharmaceuticals, renewable chemicals, fuels and food. Alagene has four partners with complementary expertise. Hylabs is an established and experienced, highly regulated service company. Reichman University is an academic partner with a commercialization mindset. The Israel Innovation Authority is the government and Aleph VC is an investment firm. Alagene is a home for innovation and R&D center in SynBio, serving as a one-stop—shop for knowledge, methods, and instrumentation to enable our customers in Israel and worldwide to get to their proof of concept. Alagene is anend to end Infrastructure supporting gene & host optimization in microbial systems. The infrastructure enables two Major Implementations- Biomanufacturing and Direct Microbial Application. One example is the development of a Dairy Milk Producing System, using Genetic Optimization and Process Optimization and Validation. Finally, Alagene shared the following recent project examples: Computational prediction for introducing new genes into microbes; Precision fermentation for yeast producing dairy proteins; Bio production of psychoactive / cannabinoid molecule in yeast; Bio production of growth factors for the cultured meat industry; Developing new inhouse tools to support strain optimization; Bio production of egg protein; Computational modeling of full metabolic network in Algae; Bio production of rare sugars with a low glycemic index.
Digital Health Ecosystem- 2022 3rd Quarter ReportLevi Shapiro
Snapshot of the global digital health investment and innovation landscape, Q3 2022, prepared by FINN Partners and Galen Growth. Includes digital health funding history, 2021 digital health investment funding breakouts, winners and losers in 2022 digital health venture funding, global vernture disribution by therapeutic area, venture distribution by stage, regulatory filings by digital health area, change in venture funding by therapeutic area, global digital health funding across regions, top funded therapeutic areas, venture funding in key digital health innovation clusters and geographies, digital health funding across regions, 2022 digital health in Israel, QoQ digital health funding by region, QoQ digital health funding, five year trended digital health funding across regions, noteworthy exits in MENA, M&A, Medigate, Breezometer, AIDOC, Vayyar, Viz.ai, Cathworks, Hello Heart, Israel venture funding and exits
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
1. “Bringing world class innovations to
market by bridging discoveries into
commercial products.”
Successful Commercialization –
The Cleveland Clinic Story
Thomas Sudow
Director of Business Development
2. How Many Patients
Were Touched Today By Innovations from
the Cleveland Clinic ?
• Blood Transfusion
• Kidney Dialysis
• Angiography
• Bi-Pass Surgery
From just these 4 –
MILLIONS !!!
Add up the rest
Well over 5 Million
TODAY
3. Since 1921
A Unique Model of Care
• Four doctors share a vision
- Non-profit, physician-led
group practice
- Collaboration across
disciplines
- All physicians are salaried
- Patient-centered mission
FRANK E. BUNTS, MD
JOHN PHILLIPS, MD
GEORGE CRILE SR., MD
WILLIAM E. LOWER, MD
4. • 5.5M Patient Visits
• 43,430 Employee Caregivers
• 27 Institutes providing care in 120
subspecialties
• Locations
• Main Campus
• 8 Community Hospitals
• 16 Family Health Centers in NE Ohio
• Facilities in Florida, Nevada, Toronto & Abu
Dhabi
• EMR Leader – My Chart
• Top 4 Hospital by U.S. News & World
Report
Cleveland Clinic
8. Cleveland
Clinic
H
Fairview Hospital
Lakewood Hospital
H
Lutheran Hospital
H
Ashtabula County
Medical Center
H
Euclid Hospital
H
Hillcrest Hospital
H
South Pointe
Hospital
H
Marymount Hospital
H
Cleveland
Clinic
Florida
H
Medina
Hospital
H
Lorain Family Health
And Surgery Center
FHC
Elyria Family
Health Center
Westlake Family
Health Center
FHC
FHC Lakewood
Family Health
Center
FHC
Strongsville Family Health
and Surgery Center
FHC
Brunswick Family
Health Center
FHC
Wooster Family
Health Center
FHC
Independence Family
Health Center
FHC
Solon Family
Health Center
FHC
Chagrin Falls Family
Health Center
FHC
Beachwood Family
Health and Surgery Center
FHC
Willoughby Hills
Family Health Center
FHC
FHC
R.E. Jacobs
Health Center
Lou Ruvo Center
for Brain Health
Las Vegas, Nevada
FHC
Cleveland
Clinic
Toronto
FHC
S.T.J.
Health Center
HC
Twinsburg Family
Health Center
FHC
6.4M Patients
9. Cleveland Clinic Culture
"We are considering not only our duty to the patient of today,
but no less our duty to the patient of tomorrow."
Quality. INNOVATION. Teamwork.
Service. Integrity. Compassion.
We welcome change, encourage invention and continually
seek better, more efficient ways to achieve our goals.
George Crile, Sr., MD
Co-Founder
Cleveland Clinic
10. Cleveland Clinic Innovations
We promote innovation and expand treatment of the
sick through the deployment of technologies
developed by Cleveland Clinic and our Healthcare
Innovations Alliance Partners.
Through commercialization, we translate emerging
diagnostics, therapies, devices, health IT and
business solutions into beneficial medical products
through spin-off companies, licenses and equity
partnerships.
11. Promote Innovation via
Commercialization
• Bring new innovations into
widespread clinical practice
• Protect the intellectual property
underlying the innovations
• Optimize the value returned for those
innovations
• Grow the regional economy and
beyond
12. Areas of Focus
1. Commercialization / technology
transfer
2. Global Healthcare Innovation Alliance
3. Medical Innovation Summit
4. Centers (GCIC & NCAI)
16. Inventions by Type 2014
Medical Device
50%
Health IT
23%
Therapeutics &
Diagnostics
22%
Delivery
Solutions
5%
17. Portfolio Companies: 71
2000-
2003
2004-
2005
2006 2007
2008-
2009
2010 2011 2012 2013 2014
ART SARL CleveX Clear
Catheter
Solutions
ATI Congruent
Medical
NaviGate iComet iVHR Renovo
Biosciences
Adeo
AxioMed IntElect Tolera CardioNomic OptoQuest Image IQ Custom
Arthroplasty
Solutions
FlexLife
Health
Shield
Biotech
Centerline
Medical
CardioMEMS Merlot Revasc Cleveland
Heart
Perfusion
Solutions
SironRX Custom
Ortho
Solutions
Infuseon Jace
Medical
VBT
Cleveland
BioLabs
CSF
Therapeutics
Alios
Biopharma
Navis Renovo
Neural
YouDocs
Beauty
Enspire
DBS
Ion-VAC Cancer
Genetics
Emanate
Wireless
Peritec PrognostiX Juventas Clear
Catheter
Systems
Buckeye
Ocular
Enforcer PluronX i360Medical Cleveland
Diagnostics
ValveXchange OrthoMems AngioQuest Cleveland
HeartLab
Sivan Panacela* RelateCare
BioSil,
USA
VioQuest Explorys Incuron* Rindex Talis
Z-Kat Zin
Medical
Intellis I-Lyte IPPC
Ridgeway Simbionix Clear
Ventric
Esperion
Therapeutics Non-operatingDeviceDiagnosticsHIT Services
Monetized
Dissolved*CBLI Spin-off
18. A Comprehensive Approach
Mine for IDEAS with clinically aligned Institute Innovation Managers
Engage clinical and technical inventor peers to evaluate NEED
Assess the commercial VIABILITY and build a business case
Develop within a domain specific incubator for ENHANCEMENT, then market
Manage NEGOTIATIONS to create spin-offs, licenses and equity partnerships
Take idea through TRANSLATION to improve patient care
20. • Inventor Satisfaction
• Greater Awareness of Innovation
• Expanded Involvement
• Improved Commercial Outcomes
• Increased Transparency for Stakeholders
• Access to Clinical, Technical, & Industry
Experts
• Enhanced Quality
• Increase Value
Value Proposition & Outcomes
21. The Global Healthcare Innovations Alliance is
a collaborative network of healthcare systems,
academic institutions and corporate partners
around the world. The Alliance creates
opportunities that benefits patients everywhere
through scalable technology development and
commercialization.
22. Partnering to Realize Opportunities
The Global Healthcare Innovations Alliance
connects members with the world class
commercialization services of Cleveland
Clinic. bEach partner brings unique
capabilities, contributing to a multilateral
network.
23. In addition to innovation management and
commercialization, The Alliance aims to identify
intersections that can combine efforts in
research, clinical investigation and technology
development. The value of partnering with the
Alliance lies in the unique 360-degree
perspective on patient care and innovation,
established connections to resources
throughout the healthcare and industry
community, and a deep and wide-ranging
commercialization capabilities and expertise.
Partnering to Realize Opportunities
27. Complementary Programs
• Heart, Lung, Blood, Sleep
• Institution-Based Projects
• Establish Proof of Concept
• 1 Year Scope of Work
• Project Guidance
• Milestone Reviews
• Grant Funding
• $50K - $150K + 1:1 Match
• Next Stage: SBIR, GCIC
• Cardiovascular
• Company-Based Projects
• Early-Stage Development
• 1 Year Scope of Work
• Project Guidance
• Milestone Reviews
• Convertible Debt Funding
• $300K - $500K + 2:1 Match
• Next Stage: VC Financing
28. Global Cardiovascular Innovation
Center
Mission and Scope
• Catalyze economic development by
developing, incubating and
commercializing cardiovascular
technology
• A consortium of university, hospital,
industry, and economic development
partners within Ohio
• $60M grant from Ohio Third Frontier Project, 2007
• Also managing
• Goals:
- Job Creation: 855 at average wage of $69,500
- New Venture-Backed and Recruited Companies: 43
- Seed and Venture Capital Invested: $207M
29. GCIC Programs
• Commercialization Funding
Provide seed funding and support to new product
development
• Product Development Acceleration
Provide product management and business planning
support by industry-experienced staff
• Business Attraction
Bring new businesses to Ohio
to grow the Cardiovascular cluster
• New Company Incubation
Operate and manage incubator facility
for start-up companies
• Preclinical Investigation Capabilities
Operate state-of-art preclinical facility
for sponsored research, product development, procedure
training
30. GCIC – a Successful Catalyst and
Magnet for New Business in Ohio
• 58 Commercialization Funding Awards Granted.
- $18.6M awarded for development of 48 technologies
- Supporting 38 companies and 8 institution-based projects
• 22 New Businesses Attracted to and Operating in Ohio.
• GCIC Incubator facility supporting 30 companies.
• 861 Added Ohio Jobs
in Companies Funded, Attracted or Incubated by GCIC.
Growing steadily as companies mature
• $763 Million in Follow-on Funding, M&A Returns Secured.
Growing significantly as companies secure
additional later round financing
As of end Q4 2014
31. Commercialization Success
• Advancing technology into physician’s hands
and into service to patients
• Progress of 48 Technologies Funded…
Development
Preclinical Validation
Clinical Trials
Acquisition Transaction or In Market
8
12
12
8
Research4
32. NIH Center for Accelerated Innovations
(NCAI) at Cleveland Clinic
• Mission to improve how basic science advances and
discoveries are translated into commercially viable products
that improve patient care and advance public health.
• One of three inaugural NCAI’s established.
• $10M grant from NHLBI to Cleveland Clinic
to establish a multi-institutional consortium of academic, clinical,
government, non-profit and private sector organizations within Ohio.
• Targeting technologies to improve diagnosis, treatment, management
and prevention of heart, lung, blood and sleep disorders and diseases.
• 7 year program to provide funding and project management for
feasibility studies, regulatory, legal, and business development expertise;
and entrepreneurial training and mentorship.
35. OHIO HEALTHCARE
INNOVATION ALLIANCE
• Large Scale Assessment of Innovation Capacity
on the State level
• Disciplined Process and Propriety Evaluation
Instruments the OHIA diagnostics was
conducted to:
• Determine Level of Collaboration
• The Existence of an Innovation Infrastructure
• The Identification of a collective promising portfolio
• Determine the Potential for a State-Wide Innovation
Alliance that will Distinguish Ohio as an Innovation
Leader
36. Lessons from the Global Innovation Alliance
•Major Advantages of Collaboration
•Cross-Pollination
•Activate All Forms of Innovation: 5-Points of Star
•Access to Resources
•Leverage Scale